Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Matilde CorianòDiana GiannarelliGiulia ScartabellatiUgo De GiorgiNicole BrighiGiuseppe FornariniChiara TommasiGiulia Claire GiudiceSara Elena RebuzziSilvia PuglisiOrazio CaffoStefania KinspergherAlessia MennittoCarlo CattriniMatteo SantoniElena VerzoniAlessandro RamettaMarco StellatoAndrea MalgeriGiandomenico RovielloMatteo BrunelliAlessio SignoriGiuseppe Luigi BannaSebastiano ButiPublished in: Expert review of anticancer therapy (2023)
Tailoring treatment with pazopanib and cabozantinib was associated with better PFS/OS.